顯示第 17 至 32 項結果，共 48 項
-
Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022] (Ab01680-16.0-BT)
-
Anti-COVID-19 & SARS-CoV S glycoprotein [CR3022] (Ab01680-16.0)
-
Anti-EGFR [C225 (Cetuximab)] (Ab00279-16.0-BT)
-
Anti-EGFR [C225 (Cetuximab)] (Ab00279-16.0)
-
Anti-erbB-2 (Her-2/neu) [4D5-8 (trastuzumab)] (Ab00103-16.0-BT)
-
Anti-erbB-2 (Her-2/neu) [4D5-8 (trastuzumab)] (Ab00103-16.0)
-
Anti-Fluorescein [4-4-20 (enhanced)] (Ab00102-16.0-BT)
-
Anti-Fluorescein [4-4-20 (enhanced)] (Ab00102-16.0)
-
Anti-RSV [RSHZ19 (Felvizumab)] (Ab00729-16.0-BT)
-
Anti-RSV [RSHZ19 (Felvizumab)] (Ab00729-16.0)
-
Anti-SARS-CoV S glycoprotein [Lsc18] (Ab01993-16.0-BT)
-
Anti-SARS-CoV S glycoprotein [Lsc18] (Ab01993-16.0)
-
Anti-SARS-CoV S glycoprotein [S110] (Ab00257-16.0-BT)
-
Anti-SARS-CoV S glycoprotein [S124] (Ab00258-16.0-BT)
-
Anti-SARS-CoV-2 and SARS-CoV nucleocapsid [mBG17] (Ab02382-16.0-BT)
-
Anti-SARS-CoV-2 and SARS-CoV nucleocapsid [mBG17] (Ab02382-16.0)